自噬
肺癌
癌症研究
医学
表观遗传学
蛋白质降解
细胞凋亡
机制(生物学)
溴尿嘧啶
癌症
免疫疗法
翻译(生物学)
肺
药物开发
串扰
生物信息学
肺癌的治疗
免疫抑制
药品
计算生物学
程序性细胞死亡
死因
淋巴瘤
生物
精密医学
靶向治疗
治疗方法
平方毫米
药物发现
作者
Jirui Wen,Yuhao Zou,Tang Feng,Le Tong,司龙龙
标识
DOI:10.1097/cm9.0000000000004343
摘要
ABSTRACT: Lung cancer, the leading cause of cancer-related mortality worldwide, remains a formidable therapeutic challenge due to profound tumor heterogeneity and the emergence of drug resistance. Conventional small-molecule inhibitors that rely on an occupancy-driven mechanism are frequently undermined by acquired mutations. Proteolysis-targeting chimeras (PROTACs) represent an event-driven therapeutic strategy that enables catalytic degradation of disease-driving proteins. This review systematically summarizes recent advances in PROTAC technology for lung cancer, emphasizing its efficacy against key oncogenic drivers (e.g., EGFR, KRAS, ALK, MET) and reactivating apoptosis (e.g., via B-cell lymphoma [BCL]-2/BCL-extra-large [BCL-2/BCL-xL] degrader 753b). We further highlight potential applications targeting epigenetic regulators such as bromodomain protein 4 (BRD4) to overcome immunosuppression via programmed death ligand-1 degradation. Despite promising preclinical results, the clinical translation of PROTACs faces challenges in pharmacokinetics, tissue specificity, and resistance. Finally, we discuss emerging innovations such as next-generation degraders and advanced delivery strategies, including antibody-PROTAC conjugates (Ab-PROTACs) and nano-PROTACs, underscoring PROTACs' potential to redefine precision oncology in lung cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI